Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy


Lévi F. A., OKYAR A., Hadadi E., Innominato P. F., Ballesta A.

Annual review of pharmacology and toxicology, cilt.64, ss.89-114, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 64
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1146/annurev-pharmtox-051920-095416
  • Dergi Adı: Annual review of pharmacology and toxicology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aquatic Science & Fisheries Abstracts (ASFA), CAB Abstracts, Chemical Abstracts Core, CINAHL, EMBASE, Environment Index, International Pharmaceutical Abstracts
  • Sayfa Sayıları: ss.89-114
  • Anahtar Kelimeler: between-subjects variability, chronopharmacology, chronotherapy, circadian rhythms, precision medicine, sex specificity
  • İstanbul Üniversitesi Adresli: Evet

Özet

Today's challenge for precision medicine involves the integration of the impact of molecular clocks on drug pharmacokinetics, toxicity, and efficacy toward personalized chronotherapy. Meaningful improvements of tolerability and/or efficacy of medications through proper administration timing have been confirmed over the past decade for immunotherapy and chemotherapy against cancer, as well as for commonly used pharmacological agents in cardiovascular, metabolic, inflammatory, and neurological conditions. Experimental and human studies have recently revealed sexually dimorphic circadian drug responses. Dedicated randomized clinical trials should now aim to issue personalized circadian timing recommendations for daily medical practice, integrating innovative technologies for remote longitudinal monitoring of circadian metrics, statistical prediction of molecular clock function from single-timepoint biopsies, and multiscale biorhythmic mathematical modelling. Importantly, chronofit patients with a robust circadian function, who would benefit most from personalized chronotherapy, need to be identified. Conversely, nonchronofit patients could benefit from the emerging pharmacological class of chronobiotics targeting the circadian clock.